Tech Center 1600 • Art Units: 1631 1699
This examiner grants 46% of resolved cases
Keenan Alexander Bates is an examiner in Art Unit 1631 of Tech Center 1600, where he has 77 resolved cases. The allowance rate pct of 45.5 indicates that fewer than half of the applications reaching a final resolution result in a patent grant. This 45.5 percent rate suggests a challenging environment for applicants, requiring careful attention to claim scope and examiner concerns. The median days to allowance is 1296, which reflects a lengthy prosecution timeline for those applications that do eventually succeed. This 1296-day median indicates that practitioners should be prepared for an extended period of examination before reaching a favorable outcome in Tech Center 1600.
The most significant metric for this examiner is the interview lift pct of 79.5. This exceptionally high lift suggests that conducting an interview is a highly effective strategy for overcoming rejections and securing an allowance. By engaging in direct verbal communication, applicants can dramatically improve their chances of success beyond the 45.5 percent baseline. The 77 resolved cases provide a clear indication that interviews are a primary driver of positive outcomes in Art Unit 1631. For practitioners, leveraging this 79.5 percent lift is likely the most efficient way to navigate the 1296-day median prosecution cycle. The data underscores that while the baseline success rate is moderate, proactive engagement can significantly alter the trajectory of an application.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17272203 | ADENO-ASSOCIATED VIRAL VECTORS FOR THE TREATMENT OF BEST DISEASE | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17600820 | Compositions and Methods for Allelic Gene Drive Systems and Lethal Mosaicism | Final Rejection | The Regents of the University of California |
| 18406302 | IMMUNOSELECTED UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS (UC-MSCs) AND DOWNSTREAM BIOLOGICS | Non-Final OA | GLOBUS MEDICAL, INC. |
| 17291070 | METHODS OF CELLULAR REPROGRAMMING | Non-Final OA | BioTissue Holdings Inc. |
| 17280392 | IN VITRO GROWTH METHOD FOR HAIR FOLLICULAR EPITHELIAL STEM CELLS | Non-Final OA | RIKEN |
| 18041447 | Methods of Protecting RNA | Final Rejection | Pfizer Inc. |
| 18892177 | METHODS FOR CREATING LINKAGE OF MULTIPLE VIRAL VECTORS FOR INTRACELLULAR DELIVERY | Non-Final OA | Battelle Memorial Institute |
| 17602730 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17601581 | COMPOSITIONS AND METHODS FOR IN UTERO GENE EDITING FOR MONOGENIC LUNG DISEASE | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17275084 | AUTOMATED GENERATION AND ANALYSIS OF ORGANOIDS | Non-Final OA | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
| 18021675 | METHOD OF MAKING RECOMBINANT AAVS | Final Rejection | Oxford University Innovation Limited |
| 18021691 | PROCESS FOR MAKING A RECOMBINANT AAV LIBRARY | Final Rejection | Oxford University Innovation Limited |
| 18648087 | PRODUCTION METHOD OF MYOCARDIAL CELL LAYER, MYOCARDIAL CELL LAYER, AND USE THEREOF | Non-Final OA | OSAKA UNIVERSITY |
| 18020734 | METHOD FOR THE TREATMENT OF WWOX ASSOCIATED DISEASES | Non-Final OA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. |
| 17771662 | HLA CLASS I MOLECULES IN IN VITRO FERTILIZATION AND FURTHER MEDICAL IMPLICATIONS | Final Rejection | Intellexon GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy